Advertisement
UK markets open in 28 minutes

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.65%)
     

  • HANG SENG

    16,185.70
    -200.17 (-1.22%)
     

  • CRUDE OIL

    84.00
    +1.27 (+1.54%)
     

  • GOLD FUTURES

    2,396.80
    -1.20 (-0.05%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    49,945.91
    +677.23 (+1.37%)
     

  • CMC Crypto 200

    1,280.35
    -32.27 (-2.46%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Global Central Nervous System Therapeutics Market Report 2021: Companies are Focusing on Extensive Research and Developments Activities to Stay Competitive

Research and Markets
·3-min read

Dublin, Aug. 18, 2021 (GLOBE NEWSWIRE) -- The "Global Central Nervous System Therapeutics Market, By Drug Class, By Application, By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Central Nervous System Therapeutics Market was valued USD 82947.46 million in 2020 and is forecast to grow with an impressive CAGR of 7.4% to 2026

The market showed a steady growth in the historical years and is expected to continue to grow in the next five years too. The growth of the market can be attributed to the increasing demand for the effective treatment plans and better medication. Furthermore, the rising foreign direct investments are also contributing to the growth of the Global Central Nervous System Therapeutics Market.

The Global Central Nervous System Therapeutics Market is segmented by drug class, application, route of administration, end-user, distribution channels, and regional distribution and by company. Based on drug class the market is further fragmented into multiple sclerosis, antipsychotic, antiepileptics, analgesics & anesthetics, anti-Parkinson, and others. The multiple sclerosis sub-segment is expected to dominate the market in the future whereas antiepileptics is expected to grow at a faster rate.

ADVERTISEMENT

The application segment is further fragmented into neurodegenerative diseases, mental health and trauma, neurovascular diseases, infectious diseases, CNS cancer and others. The neurodegenerative diseases sub-segment is dominating the Central Nervous System Therapeutics Market accounting for 34.29% of total market share in 2020.

Over the forecast period, the category is expected to maintain its dominance. The rising incidence of neurodegenerative disorders such as Multiple Sclerosis, Alzheimer's and Parkinson's, as well as the high cost of treatment of these neurodegenerative disorders, are expected to boost the segmental share.

According to the Parkinson's Foundation, in United States alone, there were approximately 930,000 people suffering from Parkinson diseases in 2020 and it is estimated that by 2030, there will be around 1.2 million people in the United States with Parkinson disease. According to the National Council of Behavioral Health, approximately 70% of adults, in the United States will be exposed to some form of traumatic events once in their lifetime.

Future of the market is favorably dependent on the advancement of therapeutic drugs for central nervous system disorders. The market experiences a rising demand for effective drugs and motivating investments from pharmaceutical companies in research and development.

Competitive Landscape

Companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.

Some of the major players in the market are

  • Biogen Inc.

  • Johnson & Johnson

  • F. Hoffmann-La Roche AG

  • Novartis AG

  • Sanofi AG

  • Eli Lilly and Company Ltd.

  • Pfizer Inc.

  • Merck & Co. Inc.

  • AstraZeneca PLC

  • Teva Pharmaceutical Industries Ltd.

  • GlaxoSmithKline PLC

  • Bayer AG

  • Otsuka Holdings Co. Ltd.

  • Amgen Inc.

  • Bristol Myers Squibb Pharmaceuticals Ltd.

Report Scope:

Years considered for this report:

  • Historical Years: 2016 - 2019

  • Base Year: 2020

  • Estimated Year: 2021

  • Forecast Period: 2022 - 2026

Global Central Nervous System Therapeutics Market, By Drug Class:

  • Multiple Sclerosis

  • Antipsychotic

  • Antiepileptics

  • Analgesics & Anesthetics

  • Anti-Parkinson

  • Others

Global Central Nervous System Therapeutics Market, By Application:

  • Neurodegenerative Diseases

  • Mental Health and Trauma

  • Neurovascular Diseases

  • Infectious Diseases

  • CNS Cancer

  • Others

Global Central Nervous System Therapeutics Market, By Route of Administration:

  • Oral

  • Parenteral

  • Others

Global Central Nervous System Therapeutics Market, By End-User:

  • Hospitals

  • Clinics

  • Diagnostic Laboratories

  • Others

Global Central Nervous System Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacy

  • Online Pharmacy

  • Retail Pharmacy

Global Central Nervous System Therapeutics Market, By Region:

  • North America

  • United States

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • APAC

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • South America

  • Brazil

  • Argentina

  • Colombia

  • MEA

  • South Africa

  • Saudi Arabia

  • UAE

For more information about this report visit https://www.researchandmarkets.com/r/4744aq

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900